NASDAQ:DCOY Decoy Therapeutics 3/31/2026 Earnings Report $5.84 -0.05 (-0.85%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$5.78 -0.05 (-0.94%) As of 05/5/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Decoy Therapeutics EPS ResultsActual EPS$43.10Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ADecoy Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADecoy Therapeutics Announcement DetailsQuarterDate3/31/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Decoy Therapeutics Earnings HeadlinesDecoy Therapeutics to Present at Two Peptide Therapeutics Conferences in BostonApril 27, 2026 | prnewswire.comDecoy Therapeutics Inc. (DCOY) Discusses Corporate Overview and Pipeline Progress in Antiviral Drug Development TranscriptApril 9, 2026 | seekingalpha.comWhere the SpaceX "Tidal Wave" hits firstThe SpaceX and xAI IPO could trigger one of the largest capital shifts in market history — $1.75 trillion moving at once. When that happens, it doesn't move evenly. Analyst Dylan Jovine has identified a critical hardware supplier tied to the infrastructure Musk is scaling in Memphis. When the S-1 goes public in June, this dependency becomes impossible to ignore. | Behind the Markets (Ad)Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral PipelineApril 9, 2026 | prnewswire.comDecoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026April 6, 2026 | prnewswire.comDecoy Therapeutics Regains Nasdaq Compliance After Reverse SplitApril 2, 2026 | tipranks.comSee More Decoy Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Decoy Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Decoy Therapeutics and other key companies, straight to your email. Email Address About Decoy TherapeuticsSalarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.View Decoy Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026onsemi Stock Dips After Earnings: Why the Dip Is BuyableTSLA: 3 Reasons the Stock Could Hit $400 in MayNebius Breaks Out to All-Time Highs—Here's What's Driving It.3 Reasons Analysts Love DexComMonolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Upcoming Earnings AppLovin (5/6/2026)ARM (5/6/2026)DoorDash (5/6/2026)Fortinet (5/6/2026)Marriott International (5/6/2026)Warner Bros. Discovery (5/6/2026)Apollo Global Management (5/6/2026)Cencora (5/6/2026)Cenovus Energy (5/6/2026)CVS Health (5/6/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
